Skip to main content
. Author manuscript; available in PMC: 2016 Nov 17.
Published in final edited form as: Vaccine. 2015 Sep 26;33(46):6332–6339. doi: 10.1016/j.vaccine.2015.09.015

Table I.

Hapten-specific IgMhigh and GC B cell subsets predict vaccine efficacy against nicotine

B cell subset Analysis Time point Nicotine-specific IgG titers at 35 days Vaccine efficacy on serum nicotine Vaccine efficacy on brain nicotine
IgMhigh 14 days r2= 0.23, NS r2=0.5, p< 0.01 r2= 0.44, p<0.05
swIg 14 days r2= 0.1, NS r2=0.3, p< 0.05 r2=0.2, p< NS
GC 14 days r2= 0.34, p<0.05 r2=0.34, p< 0.05 r2=0.2, p< NS
ASC 14 days r2= 0.2, NS r2= 0.15, NS r2= 0.03, p< NS

Shown the regression coefficient (r2) between numbers of hapten-specific B cells 14 days after the first immunization and vaccine efficacy in mice with 6CMUNic-KLH and 2CMUNic-KLH (n=12 total sample size). Mice were immunized s.c. in alum on days 0, 14 and 28. Serum antibodies and vaccine effects on nicotine distribution were analyzed a week after the last immunization. NS= not significant.